Overview
Background
Professor Andrew Barbour is an academic general surgeon who specialises in upper gastrointestinal, pancreatic, melanoma and sarcoma surgery.
On completion of his training, Dr Barbour worked at the Bristol Royal Infirmary as an Upper Gastrointestinal and Hepatobiliary Surgery Fellow and then as a Surgical Oncology Fellow at the Memorial Sloan-Kettering Cancer Centre, New York.
Professor Andrew Barbour specializes in the treatment of oesophageal, gastric, and pancreatic diseases, as well as melanoma and soft tissue tumours. He has expertise in minimally invasive treatments these conditions, including robotic surgery, minimally invasive oesophagectomy, laparoscopic anti-reflux surgery (fundoplication), laparoscopic gastrectomy, and laparoscopic pancreatectomy.
Professor Barbour’s research interests are in the treatment of cancer. His academic interests have encompassed the areas of 1) clinical research, including randomised controlled clinical trials, 2) laboratory based research, including molecular biology pertinent to upper gastrointestinal disease, pancreatic cancer and melanoma, 3) translational research integrating the laboratory and clinical domains, and 4) health-related quality of life and patient reported outcomes research.
As a clinical researcher, Prof Barbour has been active in the conduct of clinical trials at Phase I, II and III levels. He was the Principal Investigator for investigator initiated, multicentre phase II trials in oesophageal (DOCTOR trial) and pancreatic cancer (GAP Trial), funded by the NH&MRC and sponsored by the Australasian Gastrointestinal Trials Group (AGITG). Both of these national trials include biological substudies with tumour tissue and blood banking and subsequent molecular analyses aimed at answering specific questions, including the identification of biomarkers of response to therapy. These studies are aimed at developing personalized, precision therapy for cancer. The DOCTOR trial was the first trial to use PET scans to “tailor” or “personalize” therapy for patients with oesophageal cancer. The GAP trial has shown that pre-operative chemotherapy is a safe strategy for patients with pancreatic cancer. Building on the GAP trial, the AGITG has undertaken the MRFF funded MASTERPLAN clinical trial for pancreatic cancer exploring th e role of stereotactic radiation in pancreatic cancer. Professor Barbour is the Chair of the AGITG Upper GI working party and a member of the AGITG Board.
Prof Barbour is a translational researcher at the School of Medicine, The University of Queensland. He is the head of Surgical Oncology Lab at the School of Medicine. His research has focused on using genomic, epigenomic, mRNA expression and next generation sequencing data to classify oesophageal adenocarcinoma (OAC), pancreatic cancer and melanoma and to identify biomarkers of outcome. His lab team was the first to identify genomic catastrophes as potential drivers for oesophageal adenocarcinoma. In addition, his lab is seeking to identify genetic markers in melanoma that will identify patients at high risk for recurrence following surgery and to identify patients who will benefit from the current exciting advances in treatment for advanced melanoma. His work in melanoma is supported by a Queensland Advancing Clinical Research Fellowship. He was also a member of the Australian Pancreatic Cancer Genome Initiative (APGI) that has published several key studies that have improved our understanding of pancreatic cancer. His lab is currently undertaking studies using next generation sequencing of tumour and circulating tumour DNA. Professor Barbour is the Chief Investigator for the Cancer Evolution Biobank based at the Translational Research Institute. This biobank contains tumour tissue and blood from patients with melanoma, oesophageal or gastric cancer linked to clinical outcomes and supports several research projects.
Availability
- Professor Andrew Barbour is:
- Available for supervision
Fields of research
Qualifications
- Doctor of Philosophy, The University of Queensland
- Faculty of Anaesthetists of the Royal Australasian College of Surgeons, Faculty of Anaesthetists of the Royal Australasian College of Surgeons
Works
Search Professor Andrew Barbour’s works on UQ eSpace
2013
Journal Article
Role of human papillomaviruses in esophageal squamous cell carcinoma
Liyanage, Surabhi S., Segelov, Eva, Garland, Suzanne M., Tabrizi, Sepehr N., Seale, Holly, Crowe, Philip J., Dwyer, Dominic E., Barbour, Andrew, Newall, Anthony T., Malik, Aisha and Macintyre, C. Raina (2013). Role of human papillomaviruses in esophageal squamous cell carcinoma. Asia-Pacific Journal of Clinical Oncology, 9 (1), 12-28. doi: 10.1111/j.1743-7563.2012.01555.x
2013
Journal Article
Impact of postoperative morbidity on long-term survival after oesophagectomy
Hii, M. W., Smithers, B. M., Gotley, D. C., Thomas, J. M., Thomson, I., Martin, I. and Barbour, A. P. (2013). Impact of postoperative morbidity on long-term survival after oesophagectomy. British Journal of Surgery, 100 (1), 95-104. doi: 10.1002/bjs.8973
2012
Journal Article
Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes
Biankin, Andrew V., Waddell, Nicola, Kassahn, Karin S., Gingras, Marie-Claude, Muthuswamy, Lakshmi B., Johns, Amber L., Miller, David K., Wilson, Peter J., Patch, Ann-Marie, Wu, Jianmin, Chang, David K., Cowley, Mark J., Gardiner, Brooke B., Song, Sarah, Harliwong, Ivon, Idrisoglu, Senel, Nourse, Craig, Nourbakhsh, Ehsan, Manning, Suzanne, Wani, Shivangi, Gongora, Milena, Pajic, Marina, Scarlett, Christopher J., Gill, Anthony J., Pinho, Andreia V., Rooman, Ilse, Anderson, Matthew, Holmes, Oliver, Leonard, Conrad ... Grimmond, Sean M. (2012). Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature, 491 (7424), 399-405. doi: 10.1038/nature11547
2012
Journal Article
Surgical management in patients with pancreatic cancer: a Queensland perspective
Wylie, Neil, Adib, Reza, Barbour, Andrew P., Fawcett, Jonathan, Hill, Alexander, Lynch, Stephen, Martin, Ian, O'Rourke, Thomas R., Puhalla, Harald, Rutherford, Leigh, Slater, Kellee, Whiteman, David C., Neale, Rachel E. and Queensland Pancreatic Cancer Study Group (2012). Surgical management in patients with pancreatic cancer: a Queensland perspective. ANZ Journal of Surgery, 83 (11), 859-864. doi: 10.1111/j.1445-2197.2012.06312.x
2012
Journal Article
Clinical issues in oesophageal adenocarcinoma: could DNA copy number hold the key?
Frankel, Adam, Nancarrow, Derek, Wayte, Nicola and Barbour, Andrew (2012). Clinical issues in oesophageal adenocarcinoma: could DNA copy number hold the key?. Anz Journal of Surgery, 82 (9), 599-606. doi: 10.1111/j.1445-2197.2012.06144.x
2012
Journal Article
Modeling the cost-effectiveness of strategies for treating esophageal adenocarcinoma and high-grade dysplasia
Gordon, Louisa G., Hirst, Nicholas G., Mayne, George C., Watson, David I., Bright, Timothy, Cai, Wang, Barbour, Andrew P., Smithers, Bernard M., Whiteman, David C. and Eckermann, Simon (2012). Modeling the cost-effectiveness of strategies for treating esophageal adenocarcinoma and high-grade dysplasia. Journal of Gastrointestinal Surgery, 16 (8), 1451-1461. doi: 10.1007/s11605-012-1911-9
2012
Journal Article
An innovative approach for locally advanced stage III cutaneous melanoma: radiotherapy, followed by nodal dissection
Foote, Matthew, Burmeister, Bryan, Dwyer, Patrick, Burmeister, Elizabeth, Lambie, Duncan, Allan, Christopher, Barbour, Andrew, Bayley, Gerard, Pullar, Andrew, Meakin, Janelle, Thomas, Janine and Smithers, Mark (2012). An innovative approach for locally advanced stage III cutaneous melanoma: radiotherapy, followed by nodal dissection. Melanoma Research, 22 (3), 257-262. doi: 10.1097/CMR.0b013e3283531335
2012
Journal Article
Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors
Andersen, Jesper B., Spee, Bart, Blechacz, Boris R., Avital, Itzhak, Komuta, Mina, Barbour, Andrew, Conner, Elizabeth A., Gillen, Matthew C., Roskams, Tania, Roberts, Lewis R., Factor, Valentina M. and Thorgeirsson, Snorri S. (2012). Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors. Gastroenterology, 142 (4), 1021-1031.e15. doi: 10.1053/j.gastro.2011.12.005
2012
Conference Publication
DOCTOR: A randomized phase II trial of preoperative cisplatin, 5-fluorouracil, and docetaxel with or without radiotherapy based on poor early response to standard chemotherapy for resectable adenocarcinoma of the esophagus and/or OG junction
Barbour, Andrew, Smithers, Bernard Mark, Burmeister, Bryan, Zalcberg, John Raymond, Spry, Nigel, Smith, Garrett, Wilson, Kate, Roff, Kate, Yip, Sonia and Walpole, Euan Thomas (2012). DOCTOR: A randomized phase II trial of preoperative cisplatin, 5-fluorouracil, and docetaxel with or without radiotherapy based on poor early response to standard chemotherapy for resectable adenocarcinoma of the esophagus and/or OG junction. 48th Annual Meeting of the American Society of Clinical Oncology (ASCO), Chicago, Il United States, 01-06 June 2012. Alexandria, VA United States: American Society of Clinical Oncology.
2012
Journal Article
Management of loco-regionally recurrent melanoma
Geere, Simone L. and Barbour, Andrew P. (2012). Management of loco-regionally recurrent melanoma. Cancer Forum, 36 (3), 166-170.
2012
Conference Publication
Gene expression analysis of EAC in association with PET response.
Wayte, Nicola, Nancarrow, Derek, Walpole, Euan Thomas, Lampe, Guy, Gotley, David, Smithers, Bernard Mark and Barbour, Andrew (2012). Gene expression analysis of EAC in association with PET response.. ASCO GI Symposium, San Diego, California, 24 January 2012. Alexandria, VA, United States: American Society of Clinical Oncology. doi: 10.1200/jco.2012.30.4_suppl.50
2011
Journal Article
Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis
Sjoquist, Katrin M., Burmeister, Bryan H., Smithers, B. Mark, Zalcberg, John R., Simes, R. John, Barbour, Andrew, Gebski, Val and for the Australasian Gastro-Intestinal Trials Group (2011). Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. Lancet Oncology, 12 (7), 681-692. doi: 10.1016/S1470-2045(11)70142-5
2011
Journal Article
Defining cure for esophageal cancer: Analysis of actual 5-year survivors following esophagectomy
Hirst, Jodi, Smithers, Bernard Mark, Gotley, David C., Thomas, Janine and Barbour, Andrew (2011). Defining cure for esophageal cancer: Analysis of actual 5-year survivors following esophagectomy. Annals of Surgical Oncology, 18 (6), 1766-1774. doi: 10.1245/s10434-010-1508-z
2011
Journal Article
Is concurrent radiation therapy required in patients receiving preoperative chemotherapy for adenocarcinoma of the oesophagus? A randomised phase II trial
Burmeister, Bryan H., Thomas, Janine M., Burmeister, Elizabeth A., Walpole, Euan T., Harvey, Jennifer A., Thomson, Damien B., Barbour, Andrew P., Gotley, David C. and Smithers, B. Mark (2011). Is concurrent radiation therapy required in patients receiving preoperative chemotherapy for adenocarcinoma of the oesophagus? A randomised phase II trial. European Journal of Cancer, 47 (3), 354-360. doi: 10.1016/j.ejca.2010.09.009
2011
Conference Publication
Genomic and genetic characterization of human Cholangiocarcinoma identifies treatment options for tyrosine kinase inhibitors
Andersen, Jesper B., Spee, Bart, Blechacz, Boris, Avital, Itzhak, Komuta, Mina, Barbour, Andrew, Roskams, Tania, Roberts, Lewis R., Factor, Valentina M. and Thorgeirsson, Snorri S. (2011). Genomic and genetic characterization of human Cholangiocarcinoma identifies treatment options for tyrosine kinase inhibitors. 62nd Annual Meeting of the American Association for the Study of Liver Diseases, San Francisco, CA, United States, 04-08 November 2011.
2011
Journal Article
Biomarkers in oesophagogastric cancers
Cameron, Andrew, Barbour, Andrew, Wayte, Nicci and Akhurst, Tim (2011). Biomarkers in oesophagogastric cancers. Cancer Forum, 35 (3), 160-166.
2010
Journal Article
Risk stratification for early esophageal adenocarcinoma: Analysis of lymphatic spread
Barbour, Andrew P., Jones, Mark, Brown, Ian, Gotley, David C., Martin, Ian, Thomas, Janine, Clouston, Andre and Smithers, B. Mark (2010). Risk stratification for early esophageal adenocarcinoma: Analysis of lymphatic spread. Annals of Surgical Oncology, 17 (9), 2494-2502. doi: 10.1245/s10434-010-1025-0
2010
Journal Article
Thoracoscopic-assisted esophagectomy for esophageal cancer: Analysis of patterns and prognostic factors for recurrence
Thomson, Iain G., Smithers, Bernard M., Gotley, David C., Martin, Ian, Thomas, Janine M., O'Rourke, Peter and Barbour, Andrew P. (2010). Thoracoscopic-assisted esophagectomy for esophageal cancer: Analysis of patterns and prognostic factors for recurrence. Annals of Surgery, 252 (2), 281-291. doi: 10.1097/SLA.0b013e3181e909a2
2009
Journal Article
Isolated limb infusion for malignant melanoma: Predictors of response and outcome
Barbour, A. P., Thomas, J., Suffolk, J., Beller, E. and Smithers, B. M, (2009). Isolated limb infusion for malignant melanoma: Predictors of response and outcome. Annals of Surgical Oncology, 16 (12), 3463-3472. doi: 10.1245/s10434-009-0717-9
2009
Journal Article
Prognostic value maximum standardized uptake value from preoperative positron emission tomography in resectable adenocarcinoma of the esophagus treated by surgery alone
Shenfine, J., Barbour, A. P., Wong, D., Martin, I., Gotley, D. C. and Smithers, B. M. (2009). Prognostic value maximum standardized uptake value from preoperative positron emission tomography in resectable adenocarcinoma of the esophagus treated by surgery alone. Diseases of the Esophagus, 22 (8), 668-675. doi: 10.1111/j.1442-2050.2009.00941.x
Funding
Current funding
Past funding
Supervision
Availability
- Professor Andrew Barbour is:
- Available for supervision
Before you email them, read our advice on how to contact a supervisor.
Supervision history
Current supervision
-
Doctor Philosophy
Haressing tumour immune responses in oesophageal cancer: towards better personalised therapeutic strategies
Principal Advisor
Other advisors: Dr Sandra Brosda
-
Master Philosophy
Retroperitoneal sarcoma: Impact of the patterns of care on patient outcomes in Queensland.
Associate Advisor
-
Doctor Philosophy
Immune regulation through bi-directional interactions between subsets of Natural Killer cells and Dendritic cells.
Associate Advisor
Other advisors: Dr Arutha Kulasinghe, Dr Camille Guillerey, Dr Gustavo Rodrigues Rossi, Associate Professor Fernando Guimaraes
-
Doctor Philosophy
Deep spatial phenotyping analysis to characterize cancer evolution
Associate Advisor
Other advisors: Dr Sandra Brosda
Completed supervision
-
2020
Doctor Philosophy
Spatial and temporal tumour evolution and genetic biomarker discovery for personalised treatment in oesophageal adenocarcinoma
Principal Advisor
-
2013
Doctor Philosophy
Genomic investigations in oesophageal adenocarcinoma: towards biomarkers of prognosis
Principal Advisor
-
2019
Doctor Philosophy
Human dendritic cell immunoprofiling in advanced melanoma patients and responses to immunotherapy
Associate Advisor
Other advisors: Honorary Professor Kristen Radford
-
2019
Doctor Philosophy
Lipid Metabolism in Barrett's Esophagus and Esophageal Adenocarcinoma
Associate Advisor
-
2016
Doctor Philosophy
In vitro and in vivo evaluation of alginate-based microparticles for oral delivery of active entities to sites of inflammation in the colon
Associate Advisor
Other advisors: Professor Peter Cabot
-
2015
Doctor Philosophy
Serum diagnostic glycoprotein biomarkers for Barrett's esophagus and esophageal adenocarcinoma
Associate Advisor
Media
Enquiries
For media enquiries about Professor Andrew Barbour's areas of expertise, story ideas and help finding experts, contact our Media team: